GLP-1 Receptor Agonists Induce Growth Hormone Secretion in Healthy Volunteers

Overview

Journal Diabetes Ther

Specialty Cardiology & Vascular Diseases

Date 2023 Feb 17

PMID 36800161

Authors

Keiu Heinla

Eero Vasar

Ingrid Reppo

Tuuli Sedman

Vallo Volke

Affiliations

Soon will be listed here.

Abstract

Introduction: Growth hormone (GH) is an essential regulator of growth, body composition and fuel metabolism and, consequently, GH secretion is under the feedback control of numerous nutritional and endocrine mediators. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have been shown to exert pleiotropic effects, including stimulation of the activity of the hypothalamic-pituitary-adrenal axis. As GLP-1RAs exert multiple metabolic effects, we hypothesised that they may also affect the secretion of GH and examined the effect of a short-acting and a long-acting GLP-1 RA on GH secretion.

Methods: This is a post hoc analysis of data from clinical trials. Two separate single-group open-label clinical trials were carried out in the ambulatory care setting with a duration of 1 and 21 days, respectively. Healthy adult male and female volunteers with no chronic illnesses or use of daily medicines were recruited for the study. The two interventions were: study 1, single dose of 10 µg exenatide administered subcutaneously (s.c.); study 2, 0.6 mg liraglutide administered s.c. once daily for 21 days.

Results: Administration of a single dose of exenatide (study 1) caused a clear increase in GH levels, peaking between 60 and 120 min post-administration. There was also a small but statistically significant decrease in luteinising hormone and testosterone levels 120 min after exenatide dosing. Administration of the long-acting GLP-1RA liraglutide daily for 21 days (study 2) elicited an increase in GH levels with no change in insulin-like growth factor-1 (IGF-1) concentrations after 3 weeks of treatment.

Conclusions: The results show that the administration of GLP-1RAs may elicit an increase in growth hormone levels. GLP-1 signalling may be a novel mechanism of regulation of GH secretion. This finding needs to be replicated in the placebo-controlled trial.

Clinical Trial Registration Numbers: NCT02089256 and NCT03160261.

Citing Articles

GLP-1 Receptor Agonists: Beyond Diabetes-What the Neurosurgeon Needs to Know.

Abdulrazeq H, Taman M, Ali R, Doberstein C, Sullivan P, Sampath P Neurosurg Pract. 2025; 5(3):e00098.

PMID: 39959894 PMC: 11783641. DOI: 10.1227/neuprac.0000000000000098.

Treatment of acromegaly-induced diabetes: an updated proposal.

Biagetti B, Araujo-Castro M, Marazuela M, Puig-Domingo M Pituitary. 2024; 28(1):15.

PMID: 39738706 DOI: 10.1007/s11102-024-01477-x.

Growth hormone/insulin-like growth factor I axis in health and disease states: an update on the role of intra-portal insulin.

Yuen K, Hjortebjerg R, Ganeshalingam A, Clemmons D, Frystyk J Front Endocrinol (Lausanne). 2024; 15():1456195.

PMID: 39665021 PMC: 11632222. DOI: 10.3389/fendo.2024.1456195.

Glucagon-like peptide-1 receptor: mechanisms and advances in therapy.

Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C Signal Transduct Target Ther. 2024; 9(1):234.

PMID: 39289339 PMC: 11408715. DOI: 10.1038/s41392-024-01931-z.

Influence of Dulaglutide on Serum Biomarkers of Atherosclerotic Plaque Instability: An Interventional Analysis of Cytokine Profiles in Diabetic Subjects-A Pilot Study.

Hachula M, Kosowski M, Basiak M, Okopien B Medicina (Kaunas). 2024; 60(6).

PMID: 38929525 PMC: 11205508. DOI: 10.3390/medicina60060908.

References

Sedman T, Heinla K, Vasar E, Volke V . Liraglutide Treatment May Affect Renin and Aldosterone Release. Horm Metab Res. 2016; 49(1):5-9. DOI: 10.1055/s-0042-109065. View

Krass M, Volke A, Runkorg K, Wegener G, Lund S, Abildgaard A . GLP-1 receptor agonists have a sustained stimulatory effect on corticosterone release after chronic treatment. Acta Neuropsychiatr. 2014; 27(1):25-32. DOI: 10.1017/neu.2014.36. View

Elbrond B, Jakobsen G, Larsen S, Agerso H, Jensen L, Rolan P . Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care. 2002; 25(8):1398-404. DOI: 10.2337/diacare.25.8.1398. View

Krass M, Runkorg K, Vasar E, Volke V . Acute administration of GLP-1 receptor agonists induces hypolocomotion but not anxiety in mice. Acta Neuropsychiatr. 2014; 24(5):296-300. DOI: 10.1111/j.1601-5215.2012.00648.x. View

Sharp P, Foley K, Vitelli F, Maneschi F, Kohner E . Growth hormone response to hyperinsulinaemia in insulin-dependent diabetics. Comparison of patients with and without retinopathy. Diabet Med. 1984; 1(1):55-8. DOI: 10.1111/j.1464-5491.1984.tb01924.x. View

Degn K, Brock B, Juhl C, Djurhuus C, Grubert J, Kim D . Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes. 2004; 53(9):2397-403. DOI: 10.2337/diabetes.53.9.2397. View

Gil-Lozano M, Romani-Perez M, Outeirino-Iglesias V, Vigo E, Brubaker P, Gonzalez-Matias L . Effects of prolonged exendin-4 administration on hypothalamic-pituitary-adrenal axis activity and water balance. Am J Physiol Endocrinol Metab. 2013; 304(10):E1105-17. DOI: 10.1152/ajpendo.00529.2012. View

Sedman T, Vasar E, Volke V . Tolerance Does Not Develop Toward Liraglutide's Glucose-Lowering Effect. J Clin Endocrinol Metab. 2017; 102(7):2335-2339. DOI: 10.1210/jc.2017-00199. View

Marathe C, Pham H, Wu T, Trahair L, Rigda R, Buttfield M . Acute Administration of the GLP-1 Receptor Agonist Lixisenatide Diminishes Postprandial Insulin Secretion in Healthy Subjects But Not in Type 2 Diabetes, Associated with Slowing of Gastric Emptying. Diabetes Ther. 2022; 13(6):1245-1249. PMC: 9174387. DOI: 10.1007/s13300-022-01258-4. View

10.

Brooks E, Bachmeier C, Vorster J, Sorbello J, Peer F, Chikani V . Copeptin is increased by nausea and vomiting during hypertonic saline infusion in healthy individuals. Clin Endocrinol (Oxf). 2021; 94(5):820-826. DOI: 10.1111/cen.14417. View

11.

Baretic M, Kusec V, Pavlic-Renar I . Glucagon-Like Peptide-1 Infusion Suppresses Aldosterone Levels in Healthy Normal-Weight Individuals: Double-Blind, Placebo-Controlled Crossover Study. Diabetes Ther. 2018; 9(6):2315-2324. PMC: 6250632. DOI: 10.1007/s13300-018-0517-y. View

12.

Farr O, Tsoukas M, Triantafyllou G, Dincer F, Filippaios A, Ko B . Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: A randomized, placebo-controlled, crossover study. Metabolism. 2016; 65(7):945-53. PMC: 4902873. DOI: 10.1016/j.metabol.2016.03.009. View

13.

Teti C, Talco M, Albertelli M, Albanese V, Minuto M, Aglialoro A . Dipeptidyl peptidase-4 inhibitors do not alter GH/IGF-I axis in adult diabetic patients. J Endocrinol Invest. 2019; 43(3):389-393. DOI: 10.1007/s40618-019-01106-6. View

14.

Hagemann D, Holst J, Gethmann A, Banasch M, Schmidt W, Meier J . Glucagon-like peptide 1 (GLP-1) suppresses ghrelin levels in humans via increased insulin secretion. Regul Pept. 2007; 143(1-3):64-8. DOI: 10.1016/j.regpep.2007.03.002. View

15.

Gentilella R, Pechtner V, Corcos A, Consoli A . Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?. Diabetes Metab Res Rev. 2018; 35(1):e3070. DOI: 10.1002/dmrr.3070. View

16.

Eissele R, Goke R, Willemer S, Harthus H, Vermeer H, Arnold R . Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest. 1992; 22(4):283-91. DOI: 10.1111/j.1365-2362.1992.tb01464.x. View

17.

Riediger T, Eisele N, Scheel C, Lutz T . Effects of glucagon-like peptide 1 and oxyntomodulin on neuronal activity of ghrelin-sensitive neurons in the hypothalamic arcuate nucleus. Am J Physiol Regul Integr Comp Physiol. 2010; 298(4):R1061-7. DOI: 10.1152/ajpregu.00438.2009. View

18.

Lanzi R, Manzoni M, Andreotti A, Malighetti M, Bianchi E, Sereni L . Evidence for an inhibitory effect of physiological levels of insulin on the growth hormone (GH) response to GH-releasing hormone in healthy subjects. J Clin Endocrinol Metab. 1997; 82(7):2239-43. DOI: 10.1210/jcem.82.7.4071. View

19.

Skov J, Frystyk J, Christiansen J . GLP-1 infusion reduces IGFBP-1 serum level in humans. Growth Horm IGF Res. 2014; 24(2-3):67-70. DOI: 10.1016/j.ghir.2014.01.003. View

20.

Agerso H, Jensen L, Elbrond B, Rolan P, Zdravkovic M . The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002; 45(2):195-202. DOI: 10.1007/s00125-001-0719-z. View